港股異動丨藥明系集體上升,美《生物安全法案》發起人突然辭職
港股藥明系集體大升,其中,藥明生物、藥明康德升超7%,藥明合聯升超6%。消息面上,當地時間3月22日,美國《生物安全法案》的發起人、美國國會眾議院“美中戰略競爭特別委員會”主席、眾議員邁克·加拉格爾在個人社交平台上宣佈將辭職。作為該法案的核心人物,這位議員提前離職或給法案帶來變數。當地時間1月25日,邁克.加拉格爾等人提出《生物安全法案》,提出將限制美國聯邦資助的醫療服務提供者使用外國對手生物技術公司的設備或服務等。《生物安全法案》目前處於“introduced”狀態,即已提交至相應的立法機構,這通常是法案生命週期的第一步。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.